RecruitingPhase 2NCT06655155
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
Studying Systemic sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- argenx
- Intervention
- Efgartigimod PH20 SC(combination_product)
- Enrollment
- 81 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (30)
- Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona, United States
- UCLA Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, California, United States
- IRIS Research and Development LLC, Plantation, Florida, United States
- University of Illinois Health Outpatient Care Center, Chicago, Illinois, United States
- DelRicht Research, LLC, New Orleans, Louisiana, United States
- Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, United States
- Thomas Jefferson University, Columbia, Maryland, United States
- University of Michigan Hospital, Ann Arbor, Michigan, United States
- Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
- Aprillus Asistencia e Investigacion, Buenos Aires, Argentina
- Instituto de Investigación Clínica TyT, Buenos Aires, Argentina
- Consultorios Médicos Dr. Doreski - Fundacion Respirar, Buenos Aires, Argentina
- Hospital General de Agudos Dr. José María Ramos Mejia, Buenos Aires, Argentina
- Sanatorio Allende S.A., Córdoba, Argentina
- Clínica Mayo de U.M.C.B. S.R.L, San Miguel de Tucumán, Argentina
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06655155 on ClinicalTrials.govOther trials for Systemic sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07402226Systemic Sclerosis DIet for GastrointESTinal SymptomsUniversity of Michigan
- RECRUITINGEARLY PHASE1NCT07355972Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSCUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNANCT07360808Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic SclerosisCytori Therapeutics
- RECRUITINGNCT07228429Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography ImagesYale University
- RECRUITINGPHASE1NCT07167537A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune DiseasesBeijing GoBroad Hospital
- RECRUITINGEARLY PHASE1NCT07000682The Clinical Study on the Treatment of SSc With UTAA91 Injection.Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNCT06865118Home-Based Clinical Management of Cardiac Complications in Systemic SclerosisOslo University Hospital
- RECRUITINGNANCT06675344The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of LifeRobyn T. Domsic, MD, MPH